Earnings Call Summary | Acurx Pharmaceuticals(ACXP.US) Q1 2024 Earnings Conference
Earnings Call Summary | Acurx Pharmaceuticals(ACXP.US) Q1 2024 Earnings Conference
The following is a summary of the Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript:
以下是Acurx製藥公司（ACXP）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Acurx Pharmaceuticals ended Q1 2024 with a cash balance of $8.9 million, up from $7.5 million at end of December 2023.
The ATM Financing Program generated gross proceeds of approximately $4.4 million through an additional sale of 1,121,793 shares.
Research and Development (R&D) expenses for the quarter totaled $1.6 million, increasing from $1 million from the same period last year due to a rise in manufacturing related costs.
General and administrative expenses were at $2.8 million, compared to $1.9 million for Q1 2023, largely due to a $0.7 million increase in professional fees and a $0.2 million increase in non-cash share-based compensation.
Q1 2024 saw a net loss of $4.4 million, or $0.28 per diluted share, an increase from a net loss of $2.9 million, or $0.25 per diluted share from the prior year period.
截至2024年第一季度，Acurx Pharmicals的現金餘額爲890萬美元，高於2023年12月底的750萬美元。
自動櫃員機融資計劃通過額外出售1,121,793股股票產生了約440萬美元的總收益。
由於製造相關成本的上升，該季度的研發（R&D）支出總額爲160萬美元，高於去年同期的100萬美元。
一般和管理費用爲280萬美元，而2023年第一季度爲190萬美元，這主要是由於專業費用增加了70萬美元，非現金股票薪酬增加了20萬美元。
2024年第一季度淨虧損440萬美元，攤薄每股虧損0.28美元，較上年同期淨虧損290萬美元或攤薄每股虧損0.25美元有所增加。
Business Progress:
業務進展：
Acurx Pharmaceuticals shared positive comparative microbiology and microbiome data for ibezapolstat, their premier antibiotic candidate, indicating its superiority to the standard treatment, vancomycin.
After securing robust preclinical, clinical, and manufacturing data, the company has been approved by the FDA to proceed to Phase 3 trials and follow the regulatory pathway for a new drug application filing for marketing approval in the U.S.
The company also received approval from the European Medicines Agency for their SME recognition application in Europe.
Planning for two Phase 3 trials is set to begin in Q4 2024, with estimated total enrollments of 900 Modified Intent-to-Treat (MITT) patients.
A strategic transaction, possibly including a partnership for further development and potential commercialization of ibezapolstat, is being actively sought by the company.
The continuation of a blinded trial and discussions on the PASTEUR Act, which if approved, could unlock additional funding for late-stage clinical trials, are notable undertakings by the company.
Acurx Pharmicals分享了其首屈一指的抗生素候選藥物ibezapolstat的正面比較微生物學和微生物組數據，這表明其優於標準療法萬古黴素。
在獲得可靠的臨床前、臨床和生產數據後，該公司已獲得 FDA 的批准，可以繼續進行三期試驗，並遵循監管途徑在美國申請上市批准的新藥申請。
該公司在歐洲的中小企業認可申請也獲得了歐洲藥品管理局的批准。
兩項3期試驗的計劃將於2024年第四季度開始，估計總入組人數爲900名改良意向治療（MITT）患者。
該公司正在積極尋求一項戰略交易，可能包括就ibezapolstat的進一步開發和潛在商業化建立合作伙伴關係。
繼續進行盲目試驗和討論《巴斯德法案》是該公司取得的顯著成果，該法案如果獲得批准，可能會爲後期臨床試驗騰出更多資金。
More details: Acurx Pharmaceuticals IR
更多詳情： Acurx 製藥 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。